BioSpace News Archive

Paradigm, the industry leader in solving catastrophic and complex health care challenges and improving lives, today announced the appointment of Chris Pricco as Chief Executive Officer (CEO) of Paradigm Specialty Networks, effective November 2 . Ken Hannigan , who has served as the division’s CEO for the past two years,

The primary completion date1 for the pivotal efficacy study to investigate mdc-IRM, an investigational subcutaneous risperidone, was reached on September 30, 2020.

Eli Lilly and Company (NYSE:LLY) will participate in the Wolfe Research Virtual Healthcare Conference on Wednesday, November 18, 2020 . Joshua Smiley , senior vice president and Lilly’s chief financial officer, will participate in a virtual fireside chat at 1:30 p.m., Eastern Time . A live audio webcast will be available on t

Biolinq , a medical device company that has developed a novel wearable biosensor platform to measure continuous glucose for the management of diabetes and other clinical conditions, has named Richard Yang as its new Chief Executive Officer. Yang brings to Biolinq more than 20 years of global experience in med-tech innovation, product development and commercial strategy, with expertise in continuous glucose monitoring (CG

Study Enrolling Patients with CLN5 and CLN7 Subtypes Aims to Help Understand Natural Disease Course and to Help Identify Potential Clinical Endpoints for Future Gene Therapy Studies

Neuronasal, Inc., a clinical-stage pharmaceutical company developing new treatments for acute mild traumatic brain injury in partnership with ATAI, announced that it has completed its pilot study intended to show nose-to-brain delivery of N-acetylcysteine in healthy volunteers.

electroCore, Inc., a commercial-stage bioelectronic medicine company, announced third quarter 2020 financial results and provided an operational update.

Inari Medical, Inc., a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced the appointment of Kevin Strange as VP of Strategy and Business Development, and Angela Ahmad as General Counsel.

Early Interim Data for TRIDENT-1 Phase 2 Study of Repotrectinib and Second Drug Candidate, TPX-0022,Recently Presented

Inari Medical, Inc., a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, reported financial results for its third quarter ended September 30, 2020.